Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease

Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear. This study aimed to explore the association of remnant cholesterol with M...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2022-08, Vol.107 (8), p.e3295-e3303
Main Authors: Huang, Hangkai, Guo, Yanjun, Liu, Zhening, Zeng, Yan, Chen, Yishu, Xu, Chengfu
Format: Article
Language:English
Subjects:
Analysis
Blood lipids
Cardiovascular diseases
Cholesterol
Fatty liver
Low density lipoproteins
Medical research
Medicine, Experimental
Mortality
Patient outcomes
Prognosis
Triglycerides
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263
cites cdi_FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263
container_end_page e3303
container_issue 8
container_start_page e3295
container_title The journal of clinical endocrinology and metabolism
container_volume 107
creator Huang, Hangkai
Guo, Yanjun
Liu, Zhening
Zeng, Yan
Chen, Yishu
Xu, Chengfu
description Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear. This study aimed to explore the association of remnant cholesterol with MAFLD and its long-term mortality. We extracted data from the NHANES Ⅲ, 1988-1994 and the linked mortality data till December 31, 2015. The association between remnant cholesterol and MAFLD was analyzed by multivariate logistic regression. Cox proportional hazards regression was performed to assess whether elevated remnant cholesterol increased all-cause and cause-specific mortalities in MAFLD patients. At baseline, 28.6% (1474/5156) of participants had MAFLD. In multivariate logistic regression, the fourth quartile of remnant cholesterol was associated with an increased risk of MAFLD compared with the first quartile (OR: 1.714, 95% CI: 1.586-1.971; P
doi_str_mv 10.1210/clinem/dgac283
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2661083539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A777587423</galeid><sourcerecordid>A777587423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263</originalsourceid><addsrcrecordid>eNptkUlrHDEQhUWIsceOrzkGQS65tK2l1eo-GuMsYAiEBHITGqk0VtAykTQO8-8tMxOfTB0K6n2vqOIh9J6SK8oouTbBJ4jXdqMNm_kbtKLLKAZJF_kWrQhhdFgk-32Gzmv9QwgdR8FP0RkXgtGZ8xV6_AEx6dSwecgBaoOSA94WsN60ikNOm6HPIo65NB182-Ps8FY3D6nr_3x7wBGaXufgDbb76nbJNJ_ToGvNxusGFjvdui_4RyjY-gq6wjt04nSocHnsF-jX57uft1-H--9fvt3e3A9mJKwNMME4rYFR5ii1ggEVehnZwqaZSQ6LE2RiVPMZzNIFoNpRzg2R2q6tYxO_QJ8Oe7cl_931_1T01UAIOkHeVcWmiZKZC7509OMB3egAyieXW9HmGVc3Ukoxy5HxTl29QvWyEL3JCZzv89cMpuRaCzi1LT7qsleUqOcI1SFCdYywGz4cT96tI9gX_H9m_AlDBJs7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2661083539</pqid></control><display><type>article</type><title>Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease</title><source>Oxford Journals Online</source><creator>Huang, Hangkai ; Guo, Yanjun ; Liu, Zhening ; Zeng, Yan ; Chen, Yishu ; Xu, Chengfu</creator><creatorcontrib>Huang, Hangkai ; Guo, Yanjun ; Liu, Zhening ; Zeng, Yan ; Chen, Yishu ; Xu, Chengfu</creatorcontrib><description>Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear. This study aimed to explore the association of remnant cholesterol with MAFLD and its long-term mortality. We extracted data from the NHANES Ⅲ, 1988-1994 and the linked mortality data till December 31, 2015. The association between remnant cholesterol and MAFLD was analyzed by multivariate logistic regression. Cox proportional hazards regression was performed to assess whether elevated remnant cholesterol increased all-cause and cause-specific mortalities in MAFLD patients. At baseline, 28.6% (1474/5156) of participants had MAFLD. In multivariate logistic regression, the fourth quartile of remnant cholesterol was associated with an increased risk of MAFLD compared with the first quartile (OR: 1.714, 95% CI: 1.586-1.971; P &lt;0.001). In participants with normal levels of triglyceride, LDL- and HDL-cholesterol, the relationship between remnant cholesterol and MAFLD risk remained significant (OR: 1.346, 95% CI: 1.248-1.761; P &lt;0.001). During a median follow-up of 307 months, MAFLD patients with serum remnant cholesterol in the fourth quartile were associated with a higher risk of all-cause mortality (HR: 2.183, 95% CI: 1.825-2.407; P &lt;0.001), as well as a higher risk of cardiovascular mortality (HR: 2.346, 95% CI: 2.046-2.885; P &lt;0.001) and cancer-related mortality (HR: 2.366, 95% CI: 1.864-2.932; P &lt;0.001) compared with MAFLD patients in the first quartile. Remnant cholesterol was independently associated with the risk of MAFLD and predicted all-cause, cardiovascular, and cancer-related mortalities in MAFLD patients.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgac283</identifier><identifier>PMID: 35521833</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Analysis ; Blood lipids ; Cardiovascular diseases ; Cholesterol ; Fatty liver ; Low density lipoproteins ; Medical research ; Medicine, Experimental ; Mortality ; Patient outcomes ; Prognosis ; Triglycerides ; Type 2 diabetes</subject><ispartof>The journal of clinical endocrinology and metabolism, 2022-08, Vol.107 (8), p.e3295-e3303</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>COPYRIGHT 2022 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263</citedby><cites>FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263</cites><orcidid>0000-0002-6172-1253</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35521833$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Hangkai</creatorcontrib><creatorcontrib>Guo, Yanjun</creatorcontrib><creatorcontrib>Liu, Zhening</creatorcontrib><creatorcontrib>Zeng, Yan</creatorcontrib><creatorcontrib>Chen, Yishu</creatorcontrib><creatorcontrib>Xu, Chengfu</creatorcontrib><title>Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear. This study aimed to explore the association of remnant cholesterol with MAFLD and its long-term mortality. We extracted data from the NHANES Ⅲ, 1988-1994 and the linked mortality data till December 31, 2015. The association between remnant cholesterol and MAFLD was analyzed by multivariate logistic regression. Cox proportional hazards regression was performed to assess whether elevated remnant cholesterol increased all-cause and cause-specific mortalities in MAFLD patients. At baseline, 28.6% (1474/5156) of participants had MAFLD. In multivariate logistic regression, the fourth quartile of remnant cholesterol was associated with an increased risk of MAFLD compared with the first quartile (OR: 1.714, 95% CI: 1.586-1.971; P &lt;0.001). In participants with normal levels of triglyceride, LDL- and HDL-cholesterol, the relationship between remnant cholesterol and MAFLD risk remained significant (OR: 1.346, 95% CI: 1.248-1.761; P &lt;0.001). During a median follow-up of 307 months, MAFLD patients with serum remnant cholesterol in the fourth quartile were associated with a higher risk of all-cause mortality (HR: 2.183, 95% CI: 1.825-2.407; P &lt;0.001), as well as a higher risk of cardiovascular mortality (HR: 2.346, 95% CI: 2.046-2.885; P &lt;0.001) and cancer-related mortality (HR: 2.366, 95% CI: 1.864-2.932; P &lt;0.001) compared with MAFLD patients in the first quartile. Remnant cholesterol was independently associated with the risk of MAFLD and predicted all-cause, cardiovascular, and cancer-related mortalities in MAFLD patients.</description><subject>Analysis</subject><subject>Blood lipids</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Fatty liver</subject><subject>Low density lipoproteins</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Triglycerides</subject><subject>Type 2 diabetes</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptkUlrHDEQhUWIsceOrzkGQS65tK2l1eo-GuMsYAiEBHITGqk0VtAykTQO8-8tMxOfTB0K6n2vqOIh9J6SK8oouTbBJ4jXdqMNm_kbtKLLKAZJF_kWrQhhdFgk-32Gzmv9QwgdR8FP0RkXgtGZ8xV6_AEx6dSwecgBaoOSA94WsN60ikNOm6HPIo65NB182-Ps8FY3D6nr_3x7wBGaXufgDbb76nbJNJ_ToGvNxusGFjvdui_4RyjY-gq6wjt04nSocHnsF-jX57uft1-H--9fvt3e3A9mJKwNMME4rYFR5ii1ggEVehnZwqaZSQ6LE2RiVPMZzNIFoNpRzg2R2q6tYxO_QJ8Oe7cl_931_1T01UAIOkHeVcWmiZKZC7509OMB3egAyieXW9HmGVc3Ukoxy5HxTl29QvWyEL3JCZzv89cMpuRaCzi1LT7qsleUqOcI1SFCdYywGz4cT96tI9gX_H9m_AlDBJs7</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Huang, Hangkai</creator><creator>Guo, Yanjun</creator><creator>Liu, Zhening</creator><creator>Zeng, Yan</creator><creator>Chen, Yishu</creator><creator>Xu, Chengfu</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6172-1253</orcidid></search><sort><creationdate>20220801</creationdate><title>Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease</title><author>Huang, Hangkai ; Guo, Yanjun ; Liu, Zhening ; Zeng, Yan ; Chen, Yishu ; Xu, Chengfu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Blood lipids</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Fatty liver</topic><topic>Low density lipoproteins</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Triglycerides</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Hangkai</creatorcontrib><creatorcontrib>Guo, Yanjun</creatorcontrib><creatorcontrib>Liu, Zhening</creatorcontrib><creatorcontrib>Zeng, Yan</creatorcontrib><creatorcontrib>Chen, Yishu</creatorcontrib><creatorcontrib>Xu, Chengfu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Hangkai</au><au>Guo, Yanjun</au><au>Liu, Zhening</au><au>Zeng, Yan</au><au>Chen, Yishu</au><au>Xu, Chengfu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>107</volume><issue>8</issue><spage>e3295</spage><epage>e3303</epage><pages>e3295-e3303</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear. This study aimed to explore the association of remnant cholesterol with MAFLD and its long-term mortality. We extracted data from the NHANES Ⅲ, 1988-1994 and the linked mortality data till December 31, 2015. The association between remnant cholesterol and MAFLD was analyzed by multivariate logistic regression. Cox proportional hazards regression was performed to assess whether elevated remnant cholesterol increased all-cause and cause-specific mortalities in MAFLD patients. At baseline, 28.6% (1474/5156) of participants had MAFLD. In multivariate logistic regression, the fourth quartile of remnant cholesterol was associated with an increased risk of MAFLD compared with the first quartile (OR: 1.714, 95% CI: 1.586-1.971; P &lt;0.001). In participants with normal levels of triglyceride, LDL- and HDL-cholesterol, the relationship between remnant cholesterol and MAFLD risk remained significant (OR: 1.346, 95% CI: 1.248-1.761; P &lt;0.001). During a median follow-up of 307 months, MAFLD patients with serum remnant cholesterol in the fourth quartile were associated with a higher risk of all-cause mortality (HR: 2.183, 95% CI: 1.825-2.407; P &lt;0.001), as well as a higher risk of cardiovascular mortality (HR: 2.346, 95% CI: 2.046-2.885; P &lt;0.001) and cancer-related mortality (HR: 2.366, 95% CI: 1.864-2.932; P &lt;0.001) compared with MAFLD patients in the first quartile. Remnant cholesterol was independently associated with the risk of MAFLD and predicted all-cause, cardiovascular, and cancer-related mortalities in MAFLD patients.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>35521833</pmid><doi>10.1210/clinem/dgac283</doi><orcidid>https://orcid.org/0000-0002-6172-1253</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 2022-08, Vol.107 (8), p.e3295-e3303
issn 0021-972X
1945-7197
language eng
recordid cdi_proquest_miscellaneous_2661083539
source Oxford Journals Online
subjects Analysis
Blood lipids
Cardiovascular diseases
Cholesterol
Fatty liver
Low density lipoproteins
Medical research
Medicine, Experimental
Mortality
Patient outcomes
Prognosis
Triglycerides
Type 2 diabetes
title Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A49%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Remnant%20cholesterol%20predicts%20long-term%20mortality%20of%20patients%20with%20metabolic%20dysfunction-associated%20fatty%20liver%20disease&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Huang,%20Hangkai&rft.date=2022-08-01&rft.volume=107&rft.issue=8&rft.spage=e3295&rft.epage=e3303&rft.pages=e3295-e3303&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgac283&rft_dat=%3Cgale_proqu%3EA777587423%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c402t-e6e46be212f11d52e15a9429268273e9f50621a38ec9a94e1af133c07adbdf263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2661083539&rft_id=info:pmid/35521833&rft_galeid=A777587423&rfr_iscdi=true